Alira Health Adds CMC Services through Acquisition of Chamow & Associates

Chamow & Associates’ expertise in biopharmaceutical product development expands Alira Health’s lifecycle of healthcare advisory services.   

News
Published on:
January 7, 2021

FRAMINGHAM, Mass. – January 7, 2021 – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announced it has acquired Chamow & Associates, a California-based integrated CMC advisory firm. This acquisition brings expertise in biologics manufacturing, quality assurance, and regulatory compliance to Alira Health’s Product Development and Regulatory practices, which now offer a full range of services, from discovery to approval, across the U.S. and EU. Chamow & Associates’ Team of Senior Advisors complement Alira Health’s existing offerings with expertise to help clients overcome CMC challenges throughout the development process.

“Our mission at Alira Health to enable healthcare transformation and support clients in the earliest stages of development, is critical to efficiently and safely shepherd innovations into the hands of patients,” said Gabriele Brambilla, Chief Executive Officer at Alira Health. Steven Chamow has built a powerful combination of CMC capabilities, technical proficiency, and biologic expertise into his firm. We are proud to welcome them to the Alira Health family, and to offer preclinical and clinical-stage biotechnology companies a lifecycle of solutions to help bring new therapies to patients.”

Gabriele Brambilla

“We are excited and honored to become part of the Alira Health network, and to join a talented team of experts with a complementary mission,” said Dr. Steven Chamow, President of Chamow & Associates. “Becoming part of the Alira Health family will allow Chamow & Associates to further build our team and greatly expand our work with clients. By adding CMC expertise and advisory to Alira Health’s suite of services, we have a tremendous opportunity to provide comprehensive support to meet the needs of pharmaceutical companies at any stage of the development process.”

 

Steven Chamow will become Alira Health’s Senior Vice President, CMC Development and will lead biopharmaceutical product development.
Lighthouse BioPartners acted as a financial advisor to Chamow & Associates for this transaction.

About Chamow & Associates:
Chamow & Associates is a leading biopharmaceutical consulting company based in the San Francisco Bay Area. Since 2008, the company has provided integrated CMC services, including molecular engineering, process development and manufacturing, quality, regulatory, and project management services, to clinical-stage biotechnology companies around the world. Chamow & Associates focuses on monoclonal antibodies and derivatives, including bispecific antibodies and antibody drug conjugates, in addition to other recombinant protein products.

Read the press release on BusinessWire here.

Related news

Regulatory
Events July 20, 2021
Webinar Recap: Risk Management & Regulatory Submissions
Download Alira Health's Senior Vice President, Regulatory Affairs, Mary McNamara-Cullinane's webinar presentation, How to Implement Risk Management into Regulatory Submissions Using(...)
Regulatory
Publications July 20, 2021
Infographic: The Pre-IND to Market Approval Roadmap in the U.S.
Download our latest infographic, The Pre-IND to Market Approval Roadmap in the U.S.
Clinical
News June 8, 2021
Alira Health Expands Its Global Clinical and Data Capabilities Through the Acquisition of CROS NT
We have acquired CROS NT, a data-driven Contract Research Organization (CRO) headquartered in Italy with offices across Europe and the United States. CROS NT provides high quality,(...)
Clinical
Multimedia June 4, 2021
Managing Relationships Between CROs and Clinical Trial Sites
Join us in this special episode of Alira Health’s Transformation Talks with a full cast of Alira Health experts.
Regulatory
Multimedia April 29, 2021
Alira Health Webinar Replay: Trends and Challenges in US and EU Combination Product Landscapes
Rewatch this timely webinar with Alira Health’s Regulatory leadership team featuring key insights and advice for U.S. and EU companies as they map out their own regulatory pathways(...)
Clinical
Publications April 6, 2021
Unlocking the Database Lock Process
In our latest whitepaper, in collaboration with CROS NT, Alira Health’s Vice President Clinical Development, Christopher Rao and Amanda Cross, US Country Manager Executive Director,(...)
Regulatory
News February 2, 2021
We Secured Breakthrough Device Designation from FDA on PEDRA Xauron Perfusion System
We are proud to announce the firm’s Regulatory practice has secured a Breakthrough Device Designation from FDA for the real-time tissue perfusion system, PEDRA Xauron Perfusion System.

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.